Program
efmirenpase alfa
Its studies are mostly in Pseudoxanthoma Elasticum · Calciphylaxis, led by BioMarin Pharmaceutical.
Furthest: phase 3, since Aug 28, 20238 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioMarin Pharmaceutical | 80 open or running | phase 3since Aug 28, 2023 | Dec 22, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 22, 2020First study: phase 2 study in Hypophosphatemic Rickets, Autosomal Recessive, 1First studyNCT04686175 · 13 enrolled · United States, Canada, France and more
- Aug 26, 2021Phase 2 study in Pseudoxanthoma ElasticumNCT05030831 · 10 enrolled · United States, United Kingdom
- Jan 26, 2023Phase 1 study in Hypophosphatemic Rickets, Autosomal Recessive, 1NCT05734196 · 9 enrolled · United States, Spain, United Kingdom
- Aug 28, 2023Phase 3 study in Hypophosphatemic Rickets, Autosomal Recessive, 1NCT06046820 · 27 enrolled · United States, Australia, Canada and more
- Feb 21, 2024Phase 1 study in CalciphylaxisNCT06283589 · 11 enrolled · United States
- Jun 12, 2024Phase 2 study in Pseudoxanthoma ElasticumNCT06462547 · 22 enrolled · United States, France, Germany and more
- Dec 11, 2024Phase 2 study in Hypophosphatemic Rickets, Autosomal Recessive, 1NCT06739980
- Mar 11, 2026Phase 3 study in Hypophosphatemic Rickets, Autosomal Recessive, 1NCT07473973 · 2 enrolled · Brazil, France, Hungary and more
- Oct 1, 2026Phase 3 study terminatedStudy stoppedNCT06046820 · “The study was terminated by the sponsor prior to planned completion based on a review of the data across indications and overall program …”
- Oct 15, 2026Phase 1 study terminatedStudy stoppedNCT05734196 · “The study was terminated by the sponsor prior to planned completion based on a review of the data across indications and overall program …”
- Oct 19, 2026Phase 2 study terminatedStudy stoppedNCT06462547 · “The study was terminated by the sponsor prior to planned completion based on a review of the data across indications and overall program …”
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07473973Hypophosphatemic Rickets, Autosomal Recessive, 1 · Brazil, France, Hungary and more | 3 | Terminated | Aug 31, 2026 | 2 |
| NCT06739980Hypophosphatemic Rickets, Autosomal Recessive, 1 | 2 | Withdrawn | Mar 31, 2027 | 0 |
| NCT06462547Pseudoxanthoma Elasticum · United States, France, Germany and more | 2 | Terminated | Sep 30, 2026 | 22 |
| NCT06283589Calciphylaxis · United States | 1 | Completed | Jul 27, 2024 | 11 |
| NCT06046820Hypophosphatemic Rickets, Autosomal Recessive, 1 · United States, Australia, Canada and more | 3 | Terminated | Jan 29, 2026 | 27 |
| NCT05734196Hypophosphatemic Rickets, Autosomal Recessive, 1 · United States, Spain, United Kingdom | 1 | Terminated | Sep 29, 2026 | 9 |
| NCT05030831Pseudoxanthoma Elasticum · United States, United Kingdom | 2 | Completed | Jul 9, 2024 | 10 |
| NCT04686175Hypophosphatemic Rickets, Autosomal Recessive, 1 · United States, Canada, France and more | 2 | Completed | Oct 29, 2024 | 13 |
How it is read
Names in the registry
- “INZ-701”, 8 entries
Conditions, from the studies’ own filings
- Pseudoxanthoma Elasticum, 3 studies
- Calciphylaxis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.